Holen Sie sich die Stockscreener-App
177.96
1.57%
2.75
Schlusskurs vom Vortag:
$175.21
Offen:
$175.27
24-Stunden-Volumen:
219.44K
Relative Volume:
0.17
Marktkapitalisierung:
$14.36B
Einnahmen:
$8.19B
Nettoeinkommen (Verlust:
$758.19M
KGV:
19.39
EPS:
9.18
Netto-Cashflow:
$1.06B
1W Leistung:
+1.63%
1M Leistung:
-0.34%
6M Leistung:
-4.34%
1J Leistung:
-41.16%
1-Tages-Spanne:
$174.62
$178.62
1-Wochen-Bereich:
$170.27
$178.62
52-Wochen-Spanne:
$125.10
$310.54
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ICLR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
177.84 | 13.63B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
478.46 | 178.47B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
194.34 | 138.15B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
655.60 | 51.27B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
128.02 | 35.93B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
188.60 | 31.74B | 15.70B | 1.24B | 2.01B | 6.91 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-09 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-03 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2023-12-15 | Eingeleitet | Truist | Buy |
| 2023-09-13 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-09-07 | Eingeleitet | UBS | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-14 | Eingeleitet | Citigroup | Neutral |
| 2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
| 2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Equal Weight |
| 2021-03-01 | Hochstufung | UBS | Neutral → Buy |
| 2021-02-26 | Hochstufung | Truist | Hold → Buy |
| 2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
| 2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Eingeleitet | UBS | Sell |
| 2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Bestätigt | Mizuho | Neutral |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-10-27 | Bestätigt | Barclays | Equal Weight |
| 2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-27 | Bestätigt | Mizuho | Neutral |
| 2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
Icon Plc $ICLR Shares Bought by Financiere des Professionnels Fonds d investissement inc. - MarketBeat
LVM Capital Management Ltd. MI Reduces Holdings in Icon Plc $ICLR - MarketBeat
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $225 - 富途牛牛
Goldman Sachs Group Inc. Sells 106,606 Shares of Icon Plc $ICLR - MarketBeat
17,633 Shares in ICON PLC $ICLR Acquired by Greenhaven Associates Inc. - MarketBeat
Did ICON’s (ICLR) Internal CEO Succession Signal Strategic Continuity or Missed Opportunity for Change? - simplywall.st
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold - MSN
Brokerages Set Icon Plc (NASDAQ:ICLR) PT at $219.64 - MarketBeat
Jefferies Downgrades ICON Public Limited (ICLR) to Hold From Buy - Insider Monkey
TD Cowen Maintains Icon PLC(ICLR.US) With Hold Rating, Cuts Target Price to $183 - 富途牛牛
Baird Financial Group Inc. Cuts Holdings in Icon Plc $ICLR - MarketBeat
ICON plc (ICLR): Assessing Valuation as CEO Transition Confirms Stability and 2025 Guidance - simplywall.st
Jefferies Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $175 - 富途牛牛
ICON Plc and Zealand Pharma’s Petrelintide Study: A Key Update for Investors - TipRanks
ICON plc’s Latest Study on Kedrion IVIG 10% for Chronic ITP: A Market Perspective - TipRanks
Will ICON’s (ICLR) Leadership Transition Reinforce Operational Continuity or Signal a Strategic Shift? - simplywall.st
Truist Financial Reaffirms Their Buy Rating on Icon (ICLR) - The Globe and Mail
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $220 to $225 - 富途牛牛
ICON plc Reaffirms 2025 Financial Guidance Amid CEO Transition - The Globe and Mail
Icon CEO Steve Cutler to retire, Barry Balfe to succeed - TipRanks
ICON Announces CEO Transition: Dr. Steve Cutler to Retire, Barry Balfe to Take Over - AInvest
ICON plc Announces CEO Changes, Effective October 1, 2025 - MarketScreener
ICON plc Appoints Barry Balfe to the Board - MarketScreener
ICON's Leadership Transition and Market Implications: Succession Strategy and Operational Continuity in Growth-Stage Biotech Firms - AInvest
ICON names Barry Balfe as new CEO effective October 1 By Investing.com - Investing.com Australia
Icon CEO Steve Cutler to Retire; Barry Balfe to Take Reins - MarketScreener
ICON names Barry Balfe as new CEO effective October 1 - Investing.com
ICON Promotes Barry Balfe to CEO Position - AInvest
Icon Promotes COO Barry Balfe to CEO Role - MarketScreener
ICON Announces CEO Transition Effective October 1, 2025 - TipRanks
ICON Announces CEO Transition - FinancialContent
ICON’s Strategic Positioning in the Evolving CRO Landscape - AInvest
ICON plc Announces Participation in September 2025 Investor Conferences - The Globe and Mail
Baird Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $224 - 富途牛牛
Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential - AInvest
ICON plc to Participate at Upcoming Investor Conferences - PharmiWeb.com
ICON plc to Participate at Upcoming September 2025 Investor Conferences - BioSpace
ICON plc Announces Participation in Upcoming Investor Conferences - AInvest
ICON’s SWOT analysis: stock outlook amid industry headwinds and opportunities - Investing.com
Icon (ICLR) Stock Price, News & Analysis - MarketBeat
ICON’s Interim Financials Prompt Fresh Questions About Operational Agility and Efficiency for ICLR Investors - Yahoo Finance
Does ICON’s (ICLR) Interim Update Reveal New Clues About Efficiency in Clinical Research Outsourcing? - simplywall.st
ICON plc Releases Interim Financial Statements for 2025 - The Globe and Mail
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
ICON Properties Plc (Malawi) declared a final dividend of 0.15 MWK per share - AfricanFinancials
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):